Author pages are created from data sourced from our academic publisher partnerships and public sources.
National survey of extended-interval aminoglycoside dosing.
- S. K. Chuck, S. Raber, K. Rodvold, D. Areff
- Clinical infectious diseases : an official…
- 1 March 2000
A random sample survey of 500 acute care hospitals in the United States was conducted to evaluate the adoption of extended-interval aminoglycoside dosing (EIAD). The survey revealed that EIAD has… Expand
Outpatient parenteral antimicrobial-drug therapy.
- D. Gilbert, R. Dworkin, S. Raber, J. Leggett
- The New England journal of medicine
- 18 September 1997
Over the past 20 years, outpatient parenteral therapy with antimicrobial drugs has proved effective, safe, and cost effective for patients with a wide range of infectious diseases.1–4 Teams to manage… Expand
A Phase 2, Randomized, Dose-Response Trial of Taprenepag Isopropyl (PF-04217329) Versus Latanoprost 0.005% in Open-Angle Glaucoma and Ocular Hypertension
Purpose: To evaluate the safety of escalating doses of taprenepag isopropyl (PF-04217329), a selective EP2 receptor agonist administered as a topical ophthalmic solution, versus its vehicle (Stage… Expand
Ritonavir 100 mg Does Not Cause QTc Prolongation in Healthy Subjects: A Possible Role as CYP3A Inhibitor in Thorough QTc Studies
- N. Sarapa, D. Nickens, S. Raber, R. Reynolds, M. Amantea
- Clinical pharmacology and therapeutics
- 1 January 2008
To assess the QTc prolongation by ritonavir (RTV) 100 mg and explore its potential use as CYP3A inhibitor in thorough QTc (TQT) studies. Randomized, crossover study of single‐dose RTV 100 mg,… Expand
Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers.
- Hai-zhi Bu, W. Pool, E. Wu, S. Raber, M. Amantea, B. V. Shetty
- Medicine, Chemistry
- Drug metabolism and disposition: the biological…
- 1 July 2004
Metabolism and disposition of capravirine, a new non-nucleoside reverse transcriptase inhibitor, were studied in healthy male volunteers who were randomly divided into two groups (A and B) with five… Expand
Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study.
- S. Raber, Rachel Courtney, T. Maeda-Chubachi, Brad D. Simons, S. Freedman, Barbara M. Wirostko
- 1 October 2011
OBJECTIVE To evaluate short-term safety and steady-state systemic pharmacokinetics (PK) of latanoprost acid in pediatric subjects with glaucoma or ocular hypertension who received the adult… Expand
A Model‐Based Meta‐Analysis of the Effect of Latanoprost Chronotherapy on the Circadian Intraocular Pressure of Patients With Glaucoma or Ocular Hypertension
Several reports have demonstrated that the efficacy of latanoprost is influenced by the time of dosing. This model‐based meta‐analysis validates previous findings that evening dosing is superior to… Expand
Dose-Escalating, Double-Masked, Vehicle-Controlled Trial of the IOP-Reducing Effect of the EP2 Agonist PF-04217329
Pharmacodynamics of Glycopeptides in the Mouse Peritonitis Model of Streptococcus pneumoniae orStaphylococcus aureus Infection
- J. Knudsen, K. Fuursted, S. Raber, F. Espersen, N. Frimodt-Møller
- Biology, Medicine
- Antimicrobial Agents and Chemotherapy
- 1 May 2000
ABSTRACT The emergence of resistance to various antibiotics in pneumococci leaves the glycopeptides as the only antibiotics against which pneumococci have no resistance mechanism. This situation has… Expand
The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer
Background. The authors compared the pharmacokinetics of doxorubicin when administered with and without concomitant high dose cyclosporine for multidrug resistant (MDR) tumor modulation in small cell… Expand